Expectations were low in regard to sales of Gilead Sciences Inc.'s hepatitis C drugs and the company's dealmaking activity going into its first quarter earnings conference call on May 2 – and from that perspective, Gilead did not disappoint, though CEO John Milligan did pull back the curtain a little bit in regard to the company's strategy under pressure from an analyst.
Gilead reported $6.5bn in first quarter revenue, down 17% from $7.8bn in the same period of 2016; revenue from treatments...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

